标题
Poly(ADP-ribose) polymerase inhibition: past, present and future
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 19, Issue 10, Pages 711-736
出版商
Springer Science and Business Media LLC
发表日期
2020-09-03
DOI
10.1038/s41573-020-0076-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
- (2020) Ahrum Min et al. Cancers
- Role of Akt Activation in PARP Inhibitor Resistance in Cancer
- (2020) Ferenc Gallyas Jr et al. Cancers
- Repositioning PARP inhibitors for SARS‐CoV‐2 infection (COVID‐19); a new multi‐pronged therapy for ARDS?
- (2020) Nicola Curtin et al. BRITISH JOURNAL OF PHARMACOLOGY
- ‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors
- (2020) Pooja Dhileepkumar Rao et al. DRUG DISCOVERY TODAY
- Structural basis for allosteric PARP-1 retention on DNA breaks
- (2020) Levani Zandarashvili et al. SCIENCE
- Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept
- (2020) Csaba Szabo et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
- (2019) Priyancy G. Jain et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Regulating Immunity via ADP-Ribosylation: Therapeutic Implications and Beyond
- (2019) Friedrich A. Kunze et al. TRENDS IN IMMUNOLOGY
- Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
- (2019) Marianna A. Zolotovskaia et al. Frontiers in Pharmacology
- PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
- (2019) Shiv K. Gupta et al. Frontiers in Oncology
- Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
- (2019) Lucy Gentles et al. Cancers
- PARP Inhibitors and Parkinson’s Disease
- (2019) Abby L. Olsen et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation
- (2019) Alvin Z. Lu et al. BIOCHEMICAL PHARMACOLOGY
- PARP3 comes to light as a prime target in cancer therapy
- (2019) José Manuel Rodriguez-Vargas et al. CELL CYCLE
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
- (2019) Junning Cao et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Detecting the mutational signature of homologous recombination deficiency in clinical samples
- (2019) Doga C. Gulhan et al. NATURE GENETICS
- Olaparib induces browning of in vitro cultures of human primary white adipocytes
- (2019) Lilla Nagy et al. BIOCHEMICAL PHARMACOLOGY
- PARP-1 and its associated nucleases in DNA damage response
- (2019) Yijie Wang et al. DNA REPAIR
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis
- (2019) Akbar Ahmad et al. PHARMACOLOGICAL RESEARCH
- Effects of The Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis
- (2019) Akbar Ahmad et al. SHOCK
- Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
- (2019) Marie-Christine Caron et al. Nature Communications
- Poly(ADP-Ribose) Links the DNA Damage Response and Biomineralization
- (2019) Karin H. Müller et al. Cell Reports
- Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration
- (2019) Ayse Sahaboglu et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
- (2019) Michael Friedlander et al. LANCET ONCOLOGY
- Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
- (2019) Jacob J. Adashek et al. Cells
- Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
- (2019) Jing Luo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
- (2019) Nicola J. Curtin et al. Nature Reviews Clinical Oncology
- PARP Inhibition in Cancer: An Update on Clinical Development
- (2019) Esha Sachdev et al. Targeted Oncology
- Oxidative Stress Increases Endogenous Complement-Dependent Inflammatory and Angiogenic Responses in Retinal Pigment Epithelial Cells Independently of Exogenous Complement Sources
- (2019) Trakkides et al. Antioxidants
- Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3
- (2019) Yuliya V. Sherstyuk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke
- (2018) Christiane Charriaut-Marlangue et al. BRAIN BEHAVIOR AND IMMUNITY
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders
- (2018) Robert J. Henning et al. Cardiovascular Toxicology
- Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients
- (2018) Min-Young Noh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PARP Inhibition Prevents Ethanol-Induced Neuroinflammatory Signaling and Neurodegeneration in Rat Adult-Age Brain Slice Cultures
- (2018) Nuzhath Tajuddin et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- (2018) Hana Hanzlikova et al. MOLECULAR CELL
- Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke
- (2018) Youngchul Kim et al. MOLECULAR NEUROBIOLOGY
- Insights into the biogenesis, function, and regulation of ADP-ribosylation
- (2018) Michael S Cohen et al. Nature Chemical Biology
- Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
- (2018) Yanxin Lu et al. PHARMACOLOGY & THERAPEUTICS
- Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor
- (2018) Tanja Krainz et al. ACS Chemical Biology
- PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines
- (2018) Bahram Sharif-Askari et al. BREAST CANCER RESEARCH AND TREATMENT
- Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
- (2018) Brittany Haynes et al. CANCER TREATMENT REVIEWS
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.
- (2018) Elizabeth Ruth Plummer et al. JOURNAL OF CLINICAL ONCOLOGY
- CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions
- (2018) Michal Zimmermann et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interplay of Histone Marks with Serine ADP-Ribosylation
- (2018) Edward Bartlett et al. Cell Reports
- Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis
- (2018) L. McGurk et al. Acta Neuropathologica Communications
- PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome
- (2018) Antal Tapodi et al. BIOCHEMICAL PHARMACOLOGY
- Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors
- (2018) Asima Mukhopadhyay et al. BIOCHEMICAL PHARMACOLOGY
- PARPs in genome stability and signal transduction: implications for cancer therapy
- (2018) Luca Palazzo et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification
- (2018) Marie-France Langelier et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- PARP-1 (Poly[ADP-Ribose] Polymerase-1)
- (2018) Rhéure Alves-Lopes et al. HYPERTENSION
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis for DNA break recognition by ARTD2/PARP2
- (2018) Ezeogo Obaji et al. NUCLEIC ACIDS RESEARCH
- Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease
- (2018) Tae-In Kam et al. SCIENCE
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors
- (2017) Martina Ferri et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
- (2017) Rebecca Gupte et al. GENES & DEVELOPMENT
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease
- (2017) Karim Gariani et al. JOURNAL OF HEPATOLOGY
- PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis
- (2017) Partha Mukhopadhyay et al. JOURNAL OF HEPATOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
- (2017) Sani H. Kizilbash et al. MOLECULAR CANCER THERAPEUTICS
- Serine ADP-Ribosylation Depends on HPF1
- (2017) Juan José Bonfiglio et al. MOLECULAR CELL
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Expanding functions of ADP-ribosylation in the maintenance of genome integrity
- (2017) K. Martin-Hernandez et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Metabolic roles of poly(ADP-ribose) polymerases
- (2017) András Vida et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation
- (2017) Harald Schuhwerk et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Poly ADP-ribose polymerase-1: Beyond transcription and towards differentiation
- (2017) Tina Jubin et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Poly(ADP-ribose) polymerase activity and inhibition in cancer
- (2017) Caleb Dulaney et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
- (2017) Paul Lesueur et al. Oncotarget
- Macrodomains: Structure, Function, Evolution, and Catalytic Activities
- (2016) Johannes Gregor Matthias Rack et al. Annual Review of Biochemistry
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- NAD + Replenishment Improves Lifespan and Healthspan in Ataxia Telangiectasia Models via Mitophagy and DNA Repair
- (2016) Evandro Fei Fang et al. Cell Metabolism
- Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
- (2016) Suresh S. Ramalingam et al. CLINICAL CANCER RESEARCH
- Poly(ADP-Ribose) Polymerases in Aging - Friend or Foe?
- (2016) András Vida et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Mitochondrial poly(ADP-ribose) polymerase: The Wizard of Oz at work
- (2016) Attila Brunyanszki et al. FREE RADICAL BIOLOGY AND MEDICINE
- Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
- (2016) Zachary B Jenner et al. Future Oncology
- PARP inhibition and postinfarction myocardial remodeling
- (2016) Robert Halmosi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
- (2016) Ann-Gerd Thorsell et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
- (2016) Ying-Qing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
- (2016) Ian Gibbs-Seymour et al. MOLECULAR CELL
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia
- (2016) Fei Teng et al. NEUROCHEMICAL RESEARCH
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- ADP-ribose–derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling
- (2016) Roni H. G. Wright et al. SCIENCE
- Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity
- (2016) Jin-Chong Xu et al. Science Translational Medicine
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration
- (2016) Ayse Sahaboglu et al. Scientific Reports
- Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo
- (2016) Colin Thomas et al. EBioMedicine
- New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases
- (2015) Keun Woo Ryu et al. CHEMICAL REVIEWS
- PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice
- (2015) M. A. Ghonim et al. CLINICAL SCIENCE
- The rise and fall of poly(ADP-ribose): An enzymatic perspective
- (2015) John M. Pascal et al. DNA REPAIR
- Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
- (2015) Minesh P. Mehta et al. JOURNAL OF NEURO-ONCOLOGY
- PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function
- (2015) Mohamed A Ghonim et al. Journal of Translational Medicine
- The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
- (2015) Samuel García et al. MEDIATORS OF INFLAMMATION
- Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression
- (2015) María Isabel Rodríguez et al. MEDICINAL RESEARCH REVIEWS
- Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
- (2015) Felix Y. Feng et al. MOLECULAR CELL
- PARPs and ADP-Ribosylation: 50 Years … and Counting
- (2015) W. Lee Kraus MOLECULAR CELL
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
- (2015) Sharon McGonigle et al. Oncotarget
- Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
- (2014) M J Patterson et al. BRITISH JOURNAL OF CANCER
- Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle
- (2014) Eija Pirinen et al. Cell Metabolism
- Tankyrase Inhibitors as Therapeutic Targets for Cancer
- (2014) Ahmed Kamal et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Protein ADP-ribosylation and the cellular response to DNA strand breaks
- (2014) K.W. Caldecott DNA REPAIR
- Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3
- (2014) Carole Beck et al. EXPERIMENTAL CELL RESEARCH
- Nitric Oxide (NO) Releasing Poly ADP-ribose Polymerase 1 (PARP-1) Inhibitors Targeted to Glutathione S-Transferase P1-Overexpressing Cancer Cells
- (2014) Anna E. Maciag et al. JOURNAL OF MEDICINAL CHEMISTRY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice
- (2014) Kunal Kapoor et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP-ribosyl)ation signal
- (2014) Paul A. DaRosa et al. NATURE
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy
- (2014) M Li et al. ONCOGENE
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
- (2014) Selvi Durmus et al. PHARMACEUTICAL RESEARCH
- Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis
- (2014) S. A. Andrabi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP Inhibitor with Selectivity Toward ADP-Ribosyltransferase ARTD3/PARP3
- (2013) Anders E. G. Lindgren et al. ACS Chemical Biology
- Parp-2 is required to maintain hematopoiesis following sublethal -irradiation in mice
- (2013) J. Farres et al. BLOOD
- The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling
- (2013) Laurent Mouchiroud et al. CELL
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors
- (2013) Francesca Donà et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Co-ordination of base excision repair and genome stability
- (2013) Jason L. Parsons et al. DNA REPAIR
- Tankyrases as drug targets
- (2013) Lari Lehtiö et al. FEBS Journal
- The recognition and removal of cellular poly(ADP-ribose) signals
- (2013) Eva Barkauskaite et al. FEBS Journal
- Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis
- (2013) Amit Kamboj et al. Journal of Neuroinflammation
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Poly(ADP-ribose): PARadigms and PARadoxes
- (2013) Alexander Bürkle et al. MOLECULAR ASPECTS OF MEDICINE
- Poly(ADP-ribose) signaling in cell death
- (2013) László Virág et al. MOLECULAR ASPECTS OF MEDICINE
- PARP-1 and gene regulation: Progress and puzzles
- (2013) W. Lee Kraus et al. MOLECULAR ASPECTS OF MEDICINE
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss
- (2013) Yunjong Lee et al. NATURE NEUROSCIENCE
- Base Excision Repair
- (2013) H. E. Krokan et al. Cold Spring Harbor Perspectives in Biology
- The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
- (2013) Silvana B. De Lorenzo et al. Frontiers in Oncology
- The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
- (2012) Péter Bai et al. Cell Metabolism
- Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes
- (2012) Péter Bai et al. FEBS LETTERS
- Poly(ADP-Ribose) Polymerase 1 Inhibition Improves Coronary Arteriole Function in Type 2 Diabetes Mellitus
- (2012) Soo-Kyoung Choi et al. HYPERTENSION
- Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor
- (2012) Joana C d’Avila et al. Journal of Neuroinflammation
- Reprogramming cellular events by poly(ADP-ribose)-binding proteins
- (2012) Jana Krietsch et al. MOLECULAR ASPECTS OF MEDICINE
- Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts
- (2012) P. S. Kedar et al. MOLECULAR CANCER RESEARCH
- Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
- (2012) Elisabet Wahlberg et al. NATURE BIOTECHNOLOGY
- Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
- (2012) Jenna L. Riffell et al. NATURE REVIEWS DRUG DISCOVERY
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
- (2012) M.-F. Langelier et al. SCIENCE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers
- (2011) Tomasz Zaremba et al. BIOCHEMICAL JOURNAL
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
- (2011) Péter Bai et al. Cell Metabolism
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice
- (2011) M. Ali et al. MOLECULAR CANCER THERAPEUTICS
- The macro domain protein family: Structure, functions, and their potential therapeutic implications
- (2011) Weidong Han et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage
- (2011) H. C. Kang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PARP inhibitors: New tools to protect from inflammation
- (2010) Vincenzo Giansanti et al. BIOCHEMICAL PHARMACOLOGY
- Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
- (2010) C. Powell et al. CANCER TREATMENT REVIEWS
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
- (2010) Dana V. Ferraris JOURNAL OF MEDICINAL CHEMISTRY
- THERAPEUTIC INJECTION OF PARP INHIBITOR INO-1001 PRESERVES CARDIAC FUNCTION IN PORCINE MYOCARDIAL ISCHEMIA AND REPERFUSION WITHOUT REDUCING INFARCT SIZE
- (2010) Jan P. Roesner et al. SHOCK
- Inhibition of matrix metalloproteinase-2 by PARP inhibitors
- (2009) Adrian C. Nicolescu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma
- (2009) Agop Y. Bedikian et al. CANCER INVESTIGATION
- Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma
- (2009) W. Sakai et al. CANCER RESEARCH
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the Peroxynitrite-Poly(ADP-Ribose) Polymerase Pathway in Human Disease
- (2008) Pal Pacher et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial
- (2008) David A. Morrow et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Tankyrase function at telomeres, spindle poles, and beyond
- (2007) Susan J. Hsiao et al. BIOCHIMIE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started